Table 3 First long-term treatments among patients with PFS
Overall (N=147) | Children (N=68) | Adults (N=79) | PFS subtypes | ||||
|---|---|---|---|---|---|---|---|
CAPS (N=59) | TRAPS (N=40) | HIDS/MKD (N=11) | FMF (N=42) | ||||
Years from first long-term treatment for PFS until canakinumab initiation | |||||||
Known, n (%) | 94 (63.9) | 46 (67.6) | 48 (60.8) | 39 (66.1) | 24 (60.0) | 4 (36.4) | 30 (71.4) |
Mean (SD) | 2.5 (3.5) | 1.8 (2.4) | 3.1 (4.2) | 2.4 (3.2) | 2.6 (3.7) | 3.8 (3.9) | 2.6 (3.8) |
First long-term treatment for PFS a , n (%) | |||||||
Oral corticosteroids | 62 (42.2) | 29 (42.6) | 33 (41.8) | 22 (37.3) | 21 (52.5) | 5 (45.5) | 18 (42.9) |
Nonsteroidal anti-inflammatory drugs | 61 (41.5) | 32 (47.1) | 29 (36.7) | 25 (42.4) | 16 (40.0) | 4 (36.4) | 18 (42.9) |
Colchicine | 56 (38.1) | 32 (47.1) | 24 (30.4) | 20 (33.9) | 10 (25.0) | 2 (18.2) | 26 (61.9) |
Methotrexate | 32 (31.8) | 6 (8.8) | 26 (32.9) | 9 (15.3) | 13 (32.5) | 3 (27.3) | 7 (16.7) |
Corticosteroid injection | 9 (6.1) | 4 (5.9) | 5 (6.3) | 1 (1.7) | 7 (17.5) | 0 (0.0) | 1 (2.4) |
Thalidomide | 1 (0.7) | 0 (0.0) | 1 (1.3) | 0 (0.0) | 1 (2.5) | 0 (0.0) | 0 (0.0) |
Biologics | |||||||
Anakinra | 26 (17.7) | 16 (23.5) | 10 (12.7) | 14 (23.7) | 4 (10.0) | 3 (27.3) | 8 (19.0) |
Adalimumab | 17 (11.6) | 5 (7.4) | 12 (15.2) | 6 (10.2) | 9 (22.5) | 1 (9.1) | 2 (4.8) |
Canakinumab | 14 (9.5) | 3 (4.4) | 11 (13.9) | 7 (11.9) | 3 (7.5) | 1 (9.1) | 3 (7.1) |
Rituximab | 5 (3.4) | 0 (0.0) | 5 (6.3) | 0 (0.0) | 4 (10.0) | 1 (9.1) | 0 (0.0) |
Etanercept | 4 (2.7) | 2 (2.9) | 2 (2.5) | 2 (3.4) | 1 (2.5) | 0 (0.0) | 1 (2.4) |
Infliximab | 4 (2.7) | 3 (4.4) | 1 (1.3) | 0 (0.0) | 1 (2.5) | 0 (0.0) | 3 (7.1) |
Rilonacept | 2 (1.4) | 2 (2.9) | 0 (0.0) | 2 (3.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Tocilizumab | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Unknown | 2 (1.4) | 1 (1.5) | 1 (1.3) | 0 (0.0) | 2 (5.0) | 0 (0.0) | 0 (0.0) |